AMGEN INC

FDA questions Amgen’s Tavneos data integrity for rare liver disease. Discover how regulatory scrutiny, post‑approval evidence, and market impact shape this therapy’s future.

Amgen hires an independent review to counter the FDA’s Tavneos withdrawal proposal, aiming to prove efficacy and safety amid rising hepatotoxicity concerns.

Amgen’s VESALIUS‑CV trial shows Evolocumab cuts major heart events by 34% in high‑risk diabetics, while real‑world GLP‑1 data reveal adherence gaps that need new strategies.

Amgen’s ADA 86th presentation reveals Repatha® cuts CV events by 23% in high‑risk diabetics and shows real‑world GLP‑1 persistence improves HbA1c and weight, highlighting new obesity‑centric therapies.

Amgen’s rising stock shows biotech resilience amid market swings, powered by proven drugs like Repatha® and a pipeline of oncology, nephrology and inflammation therapies that promise sustained growth.

Amgen’s senior leaders will present at the 2026 Jefferies Global Healthcare Conference, covering its therapeutic pipeline, financial outlook, and global strategy.

Amgen invests $300 M to expand its Puerto Rico biomanufacturing facility, boosting global supply, job creation and U.S. production resilience.

Amgen’s latest earnings reveal modest revenue growth, improving margins, and cautious optimism amid macro‑economic headwinds—how it navigates reimbursement, supply chain, and next‑gen biopharma technologies.

Amgen’s institutional investor confidence and DCF valuation reveal robust growth, efficient R&D spend, and a 21.5% profit margin, positioning the biotech firm favorably amid evolving value‑based reimbursement models.

Amgen’s CTO exit and tech‑leadership reshuffle drive AI‑powered R&D, faster biologics and smarter payer deals, boosting margins and patient access.